StockNYSE · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$ELAN
Elanco Animal Health Inc
Elanco develops and sells animal health products and services to help prevent and treat disease in pets and farm animals. Its customers include farmers, pet owners, veterinarians, distributors, retailers and animal producers. Elanco operates as a single segment and sells products under approximately 200 brands in more than 90 countries. It is headquartered in Indianapolis, Indiana. Its pet health portfolio includes parasiticides, dermatology treatments, vaccines and pain therapies, including the Advantage, Credelio and Tru families, Seresto, Zenrelia and Galliprant. Farm animal products for cattle, poultry, swine and sheep include medicated feed additives, antibiotics, vaccines, insecticides and enzymes, such as Rumensin, Experior, Maxiban and Monteban. Elanco sells pet products mainly through third-party distributors and retailers and directly to veterinarians; farm animal products are sold through distributors and directly to producers.
Elanco Animal Health's drug Experior, approved by the FDA to reduce ammonia emissions in cattle, has faced scrutiny due to reported health issues. Studies linked it to lameness, bloat, and deaths, though the FDA attributed these to other factors. Despite concerns, Experior generated over $200M in 2025 sales, with over half of U.S. feedlot cattle receiving it. The FDA and Elanco defend its safety and efficacy.
JP Morgan reaffirmed its Overweight rating on Elanco Animal Health and increased its price target to $35 from $33, suggesting a 36% upside from the Nov 6 close of $25.74. Recent analyst price targets for the company range from $24 to $32.
KeyBanc maintained an Overweight rating and $30.00 price target for Elanco Animal Health (NYSE:ELAN), citing strong Q3 results and confidence in 2027 outlook. Gross margin expanded to 56.1% YoY. Elanco reported Q3 adjusted earnings of $0.27 per share, beating estimates, and raised its full-year outlook. Analysts expect mid-single-digit organic revenue growth and further gross margin expansion.
via TradingView
ELAN sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ELAN (Elanco Animal Health Inc). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent ELAN coverage spans financial news, earnings and regulation.
What's driving ELAN
Safety concerns may trigger regulatory scrutiny and investor caution.
JP Morgan reaffirmed its Overweight rating on Elanco Animal Health and increased its price target to $35 from $33, suggesting a 36% upside from the Nov 6 close of $25.74. Recent analyst price targets for the company range from $24 to $32.
AlphAI scores every news story that mentions ELAN with an AI model for sentiment and relevance, and aggregates insider trades from Elanco Animal Health Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Elanco Animal Health's drug Experior, approved by the FDA to reduce ammonia emissions in cattle, has faced scrutiny due to reported health issues. Studies linked it to lameness, bloat, and deaths, though the FDA attributed these to other factors. Despite concerns, Experior generated over $200M in 2025 sales, with over half of U.S. feedlot cattle receiving it. The FDA and Elanco defend its safety and efficacy.
JP Morgan reaffirmed its Overweight rating on Elanco Animal Health and increased its price target to $35 from $33, suggesting a 36% upside from the Nov 6 close of $25.74. Recent analyst price targets for the company range from $24 to $32.
KeyBanc maintained an Overweight rating and $30.00 price target for Elanco Animal Health (NYSE:ELAN), citing strong Q3 results and confidence in 2027 outlook. Gross margin expanded to 56.1% YoY. Elanco reported Q3 adjusted earnings of $0.27 per share, beating estimates, and raised its full-year outlook. Analysts expect mid-single-digit organic revenue growth and further gross margin expansion.
Elanco (ELAN) reported Q3 2026 revenue of $1.265B, up 11% YoY, and raised its 2026 sales outlook to $5.155B-$5.18B. The company also increased guidance for Adjusted EBITDA and Adjusted EPS, citing strong growth in Pet Health and Farm Animal segments. Elanco's net leverage ratio reached 2.9x, unlocking capital allocation flexibility.
Elanco Animal Health (ELAN) released survey results showing 93% of pet owners maintained or increased pet spending in the past three months, with 32% increasing spend. The survey also found that pet health is a priority, with 87% of owners valuing their pet's wellbeing as much or more than their own. The data suggests strong future demand for pet health products and services.
Humana (HUM), Elanco (ELAN), and Moderna (MRNA) report earnings on Nov. 6. Humana's Medicare Advantage update is key for retirement investors. Elanco saw 8% organic revenue growth in Q2. Moderna's stock surged 737% this year. Analysts expect varied EPS and revenue changes for Q3. Watch medical costs, supply, and cash burn trends.
A 12-month study found that Advantix (Elanco) spot-on treatment prevented all Leishmania infantum infections in 20 treated dogs, while 40% of 20 untreated dogs became infected. The study was conducted in a highly endemic region of Greece during the sand fly season. Advantix contains imidacloprid 10% and permethrin 50%.
Morgan Stanley kept Elanco Animal Health at Equal-Weight but reduced its price target to $25 from $26, a 3.8% cut. The new target suggests 10.4% upside from the Oct 28 close of $22.65, according to the firm.
Elanco Animal Health (ELAN) fell 3.36% after Jefferies downgraded it to hold and cut its price target. Patterson-UTI (PTEN) dropped 3.49% due to lower oil prices. GE Aerospace (GE) declined 3.67% following strong Q3 earnings, while Howmet Aerospace (HWM) fell 3.82% on lack of new catalysts.
Wall Street analysts released research calls on various companies. Upgrades include Akamai (AKAM) to Strong Buy, BlackRock (BLK) to Buy, and Venture Global (VG) to Overweight. Downgrades include Apple (AAPL) to Hold, Elanco (ELAN) to Hold, and Zoetis (ZTS) to Hold. Initiations include Ford (F) with Overweight and Sunoco (SUN) with Overweight. Markets were mixed, with Nasdaq futures lower and Treasury yields higher.